click below
click below
Normal Size Small Size show me how
WEEK 9:
Endocrine pancreas and hormones:
| Question | Answer |
|---|---|
| insulin synthesised in | pancreatic b-cells |
| insulin formed as | proinsulin |
| insulin half life | 5-9 minutes |
| insulin biosynthesis includes | preproinsulin synthesis in the RER undergoing signal sequence cleavage to proinsulin then passed via micro-vesicles into golgi to become insulin via cleavage of C-peptide |
| proinsulin conversion to insulin involves | proconvertase 2 and proconvertase 1 (PC1 & PC2) which cleave the ends of proinsulin and then carboxypeptidase H (CPH) cleaves more to make one molecule insulin and molecule c peptide |
| ratio of insulin to c peptide after insulin biosynthesis | 1:1 ratio (1 molecule insulin and 1 molecule c peptide) |
| how is insulin exported out cell | insulin and c peptide packaged together as crystalloid core (6 insulin : 2 Zn2+) which is exocytosised to plasma membrane using Ca2+ and ATP |
| what is required for exocytosis of insulin to plasma membrane | Ca2+ and ATP |
| how is insulin released (4) | increase of blood glucose, amino acid and fatty acids, gut hormones, glucagon, sympathetic neural control, sympathetic neural control |
| explain how blood glucose increase causes insulin release | (>5mM where rise in ATP:ADP ratio closes ATP sensitive K+ channels which depolarises membrane and opens voltage gated Ca2+ channels leading to increase insulin release) |
| nutrient stimulus for insulin release (2) | increase of blood glucose, amino acid and fatty acids |
| potentiators for insulin release (2) | gut hormones, and glucagon |
| explain how gut hormones work for insulin release | gut hormones eg GLP-1 and GIP are incretins causing insulin release |
| explain how glucagon works for insulin release | glucagon (somatostatin inhibits) paracrine signaling |
| neural control for insulin release (2) | sympathetic and parasympathetic |
| sympathetic control for insulin release | B-adrenoceptor increases insulin release and alpha 2 receptors decrease insulin release |
| effect of A2 adrenoceptors on insulin release | decrease |
| effect of muscarinic and B-adrenoceptors on insulin release | increase |
| parasympathetic control for insulin release | muscarinic increase insulin release |
| effect of glucose and insulin in liver | increase glycogen synthesis decrease glycogen breakdown decrease gluconeogenesis |
| effect of glucose and insulin on adipose tissue | increase glucose uptake increase lipogenesis and decrease lipolysis |
| effect of glucose and insulin on muscle | increase glucose uptake increase protein synthesis and decrease protein breakdown |
| glucagon | peptide hormone synthesised in islet a-cells |
| when is glucagon released | when low blood glucose (<3.5mM) and parasympathetic and sympathetic neural stimulation and amino acids |
| glucagon inhibited by | high blood glucose as well as paracrine effects of insulin and somatostatin |
| glucagon produced from | long precursor (proglucagon) |
| main actions of glucagon | raise blood glucose by stimulating hepatic glucogenolysis, stimulating hepatic gluconeogenesis, and stimulate lipolysis |
| somatostatin | peptide hormone synthesised in islet detla cells |
| somatostatin present in | GIT and CNS |
| somatostatin inhibits | glucagon and insulin secretion by a paracrine mechanism (action understood but not physiological purpose) |
| normal range of blood glucose | 4-8mmol/L |
| hormones causing glucose production | glucagon, adrenaline, growth hormone and cortisol |
| adrenaline | provision of energy for emergencies and exercise (ie severe hypoglycaemia) |
| cortisol | mobilisation of fuels during adaptation to stress (and prolonged hypoglycaemia) |
| growth hormone | promotion of growth (Smaller role in normal metabolism) and prolonged hypoglycaemia |
| GH does what to glucose uptake and use | decrease |
| cortisol does what to glucose uptake and use | decrease |
| adrenaline/noradrenaline do what to glucose uptake and use | decrease |
| diabetes mellitus (chronic hyperglycaemia) | inappropriate glucose homeostasis (most common endocrine disorder) |